Department of Gastroenterology, Nutrition, and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan.
Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, Osaka, Japan.
Pediatr Int. 2021 Jan;63(1):46-52. doi: 10.1111/ped.14363. Epub 2021 Jan 19.
The effectiveness of growth hormone (GH) treatment for height gain in short-stature children born small for gestational age (SGA) with extremely low birthweight (ELBW; birthweight <1,000 g) remains largely unknown.
In study 1, 35 prepubertal Japanese children born SGA with ELBW were categorized into three groups based on the presence or absence of catch-up growth by age 3 (CU(+) and CU(-), respectively) and GH treatment (GH(+) and GH(-), respectively). Height standard deviation (SD) scores (HT-SDS) in the CU-/GH+ group (n = 19) were compared with those in the age-matched CU+/GH- (n = 9) and CU-/GH- groups (n = 7). In study 2, 66 prepubertal Japanese SGA children treated with GH were divided into three groups by birthweight: <1,000 g (n = 19), 1,000-2,000 g (n = 20), and >2,000 g (n = 27). Changes in HT-SDS during the initial 3 years of GH treatment were compared among the three groups.
In study 1, the mean HT-SDS in the CU-/GH+ group (-1.15 SD) was similar to that in the CU+/GH- group (-1.39 SD) but higher than that in the CU-/GH- group (-2.24 SD). In study 2, GH achieved a height gain of +1.62 SD in the ELBW group, which was similar to that in the other groups (1,000-2,000 g: +1.46 SD, >2,000 g: +1.53 SD).
Growth hormone treatment in short-stature children born SGA with ELBW increased HT-SDS, which was similar to that in SGA children born with a birthweight ≥1,000 g. These results indicate that GH treatment may be an effective approach to promote adequate growth recovery for short-stature children born SGA with ELBW.
极低出生体重（ELBW；出生体重<1000 克）的生长激素（GH）治疗对身材矮小、胎龄小（SGA）儿童身高增长的有效性尚不清楚。
在研究 1 中，根据 3 岁时是否存在追赶生长（分别为 CU(+)和 CU(-)）和 GH 治疗（分别为 GH(+)和 GH(-)），将 35 名日本 ELBW 的 SGA 青春期前儿童分为三组。CU-/GH+组（n=19）的身高标准差（HT-SDS）评分与年龄匹配的 CU+/GH-组（n=9）和 CU-/GH-组（n=7）进行比较。在研究 2 中，根据出生体重将 66 名接受 GH 治疗的日本 SGA 青春期前儿童分为三组：<1000g（n=19）、1000-2000g（n=20）和>2000g（n=27）。比较三组儿童 GH 治疗初始 3 年内 HT-SDS 的变化。
在研究 1 中，CU-/GH+组（-1.15SD）的平均 HT-SDS 与 CU+/GH-组（-1.39SD）相似，但高于 CU-/GH-组（-2.24SD）。在研究 2 中，GH 在 ELBW 组实现了身高增长 1.62SD，与其他组相似（1000-2000g：1.46SD，>2000g：1.53SD）。
GH 治疗 ELBW 的 SGA 矮小儿童增加了 HT-SDS，与出生体重≥1000g 的 SGA 儿童相似。这些结果表明，GH 治疗可能是促进 ELBW 的 SGA 矮小儿童充分生长恢复的有效方法。
